Health Care Startups Desperately Need Clinical Expertise

Key Takeaways

• Physician-led diligence improves startup success odds.
• Clinical necessity, regulatory feasibility, reimbursement viability are essential gates.
• Most VC decisions lack bedside insight, leading to stranded technologies.
• AI tools aid data gathering but cannot replace clinical judgment.
• Physicians can add value as advisors, LPs, or mentors without leaving practice.

Pulse Analysis

The health‑care venture ecosystem has exploded in the past decade, with billions of dollars chasing digital‑health apps, AI diagnostics, and novel devices. Yet a recurring pattern emerges: founders pitch sophisticated technology that ignores the realities of daily clinical practice. Without a physician’s eye on workflow integration, many solutions add steps, increase procedure time, or fail to address a genuine pain point, leaving investors with products that sit on shelves rather than in operating rooms. This mismatch not only wastes capital but also slows the delivery of innovations that could improve patient outcomes.

Dr. Harsha Moole’s experience illustrates a disciplined approach to closing that gap. He frames diligence around three non‑negotiable gates: clinical necessity—does the problem compel physicians to change behavior?; regulatory feasibility—can the product navigate FDA pathways or hospital compliance without prohibitive delays?; and reimbursement viability—are there CPT codes or payer contracts that will fund adoption? While AI‑driven analytics can quickly surface market data and competitive landscapes, they lack the tacit knowledge to predict a three‑year FDA delay or a pending CMS code review. Consequently, physician insight remains irreplaceable for assessing true commercial potential.

The path forward involves integrating clinicians into the investment pipeline without forcing them to abandon practice. Venture funds can enlist physician advisory boards, allocate a portion of capital to limited‑partner commitments from doctors, and create clinical review panels that vet deals before term sheets are issued. Networks like Dr. Moole’s 200‑strong physician cohort demonstrate how bedside experience can be scaled to inform dozens of deals annually. By aligning financial incentives with clinical expertise, the industry can reduce the prevalence of stranded technologies, accelerate time‑to‑market for high‑impact solutions, and ultimately generate better returns for investors and patients alike.